A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas

NCT00400764 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Dulanermin
DRUG: Rituximab

Sponsor

Genentech, Inc.

Collaborators

[object Object]